BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2025
BIOQUAL (OTC Pink: BIOQ) has released its unaudited financial results for the third quarter of fiscal year 2025. The company reported quarterly revenue of $14.03 million, down from $15.34 million in the same period last year.
For the nine months ended February 28, 2025, revenue decreased to $37.20 million from $46.79 million year-over-year. The company posted a quarterly net income of $936,030 ($1.05 per share), compared to $275,026 ($0.31 per share) in Q3 2024. However, for the nine-month period, BIOQUAL recorded a net loss of $951,497 (-$1.06 per share) versus a net income of $1.66 million ($1.86 per share) in the previous year.
BIOQUAL (OTC Pink: BIOQ) ha pubblicato i risultati finanziari non verificati per il terzo trimestre dell'anno fiscale 2025. L'azienda ha registrato un fatturato trimestrale di $14,03 milioni, in calo rispetto ai $15,34 milioni dello stesso periodo dell'anno scorso.
Per i nove mesi terminati il 28 febbraio 2025, il fatturato è sceso a $37,20 milioni dai $46,79 milioni dell'anno precedente. L'azienda ha riportato un utile netto trimestrale di $936.030 ($1,05 per azione), rispetto ai $275.026 ($0,31 per azione) del Q3 2024. Tuttavia, per il periodo di nove mesi, BIOQUAL ha registrato una perdita netta di $951.497 (-$1,06 per azione) rispetto a un utile netto di $1,66 milioni ($1,86 per azione) dell'anno precedente.
BIOQUAL (OTC Pink: BIOQ) ha publicado sus resultados financieros no auditados para el tercer trimestre del año fiscal 2025. La compañía reportó ingresos trimestrales de $14.03 millones, en comparación con $15.34 millones en el mismo período del año pasado.
Para los nueve meses que finalizaron el 28 de febrero de 2025, los ingresos disminuyeron a $37.20 millones desde $46.79 millones en comparación interanual. La compañía reportó un ingreso neto trimestral de $936,030 ($1.05 por acción), en comparación con $275,026 ($0.31 por acción) en el Q3 2024. Sin embargo, para el período de nueve meses, BIOQUAL registró una pérdida neta de $951,497 (-$1.06 por acción) frente a un ingreso neto de $1.66 millones ($1.86 por acción) en el año anterior.
BIOQUAL (OTC Pink: BIOQ)는 2025 회계연도 3분기 비감사 재무 결과를 발표했습니다. 이 회사는 분기 매출이 $14.03 백만으로, 지난해 같은 기간의 $15.34 백만에서 감소했다고 보고했습니다.
2025년 2월 28일로 종료된 9개월 동안 매출은 지난해 $46.79 백만에서 $37.20 백만으로 감소했습니다. 이 회사는 분기 순이익이 $936,030 ($1.05 per 주식)로, 2024년 3분기의 $275,026 ($0.31 per 주식)과 비교되었습니다. 그러나 9개월 동안 BIOQUAL은 $951,497 (-$1.06 per 주식)의 순손실을 기록했으며, 이는 지난해의 순이익 $1.66 백만 ($1.86 per 주식)과 대조적입니다.
BIOQUAL (OTC Pink: BIOQ) a publié ses résultats financiers non audités pour le troisième trimestre de l'exercice 2025. La société a annoncé un chiffre d'affaires trimestriel de $14,03 millions, en baisse par rapport à $15,34 millions au cours de la même période l'année dernière.
Pour les neuf mois se terminant le 28 février 2025, le chiffre d'affaires a diminué à $37,20 millions contre $46,79 millions d'une année sur l'autre. L'entreprise a affiché un bénéfice net trimestriel de $936.030 ($1,05 par action), comparé à $275.026 ($0,31 par action) au T3 2024. Cependant, pour la période de neuf mois, BIOQUAL a enregistré une perte nette de $951.497 (-$1,06 par action) contre un bénéfice net de $1,66 millions ($1,86 par action) l'année précédente.
BIOQUAL (OTC Pink: BIOQ) hat seine ungeprüften finanziellen Ergebnisse für das dritte Quartal des Geschäftsjahres 2025 veröffentlicht. Das Unternehmen berichtete von einem Quartalsumsatz von $14,03 Millionen, ein Rückgang von $15,34 Millionen im gleichen Zeitraum des Vorjahres.
Für die neun Monate bis zum 28. Februar 2025 sank der Umsatz auf $37,20 Millionen von $46,79 Millionen im Jahresvergleich. Das Unternehmen erzielte einen Quartalsnettogewinn von $936.030 ($1,05 pro Aktie), verglichen mit $275.026 ($0,31 pro Aktie) im Q3 2024. Für den Neunmonatszeitraum verzeichnete BIOQUAL jedoch einen Nettoverlust von $951.497 (-$1,06 pro Aktie) im Vergleich zu einem Nettogewinn von $1,66 Millionen ($1,86 pro Aktie) im Vorjahr.
- Q3 2025 net income increased significantly to $936,030 from $275,026 in Q3 2024
- Q3 2025 EPS grew to $1.05 from $0.31 year-over-year
- Q3 2025 revenue declined 8.5% to $14.03M from $15.34M year-over-year
- Nine-month revenue decreased 20.5% to $37.20M from $46.79M
- Nine-month performance showed net loss of $951,497 versus profit of $1.66M previous year
|
|||||||||||||
Nine Months Ended |
Three Months Ended |
|
|||||||||||
February 28 & 29, |
February 28 & 29, |
|
|||||||||||
|
2025 |
|
|
2024 |
|
2025 |
|
2024 |
|
||||
Revenue |
$ |
37,198,902 |
|
$ |
46,792,353 |
$ |
14,032,982 |
$ |
15,344,027 |
|
|||
|
|||||||||||||
(Loss) Income Before Income Tax |
$ |
(1,312,897 |
) |
$ |
2,288,970 |
$ |
1,291,330 |
$ |
379,226 |
|
|||
|
|||||||||||||
Net (Loss) Income |
$ |
(951,497 |
) |
$ |
1,659,170 |
$ |
936,030 |
$ |
275,026 |
|
|||
|
|||||||||||||
Basic Earnings per Share |
|
||||||||||||
of Common Stock |
$ |
(1.06 |
) |
$ |
1.86 |
$ |
1.05 |
$ |
0.31 |
|
|||
|
|||||||||||||
Diluted Earnings per Share |
|
||||||||||||
of Common Stock |
$ |
(1.06 |
) |
$ |
1.86 |
$ |
1.05 |
$ |
0.31 |
|
|||
|
|||||||||||||
Weighted Average |
|
||||||||||||
Number of Shares Outstanding |
|
|
|
||||||||||
For Basic Earnings Per Share |
|
894,416 |
|
|
894,416 |
|
894,416 |
|
894,416 |
|
|||
|
|||||||||||||
Weighted Average |
|
||||||||||||
Number of Shares Outstanding |
|
||||||||||||
For Diluted Earnings Per Share |
|
894,394 |
|
|
894,401 |
|
894,383 |
|
894,407 |
|
|||
For more detail related to the fiscal year 2025 unaudited third quarter results, please visit our web site at www.bioqual.com. |
|
||||||||||||
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government and commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250411471321/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)
Source: BIOQUAL, Inc.
FAQ
What was BIOQUAL's (BIOQ) revenue for Q3 2025?
How much net income did BIOQ generate in Q3 2025?
What was BIOQUAL's (BIOQ) nine-month performance in fiscal 2025?
How did BIOQ's Q3 2025 earnings compare to Q3 2024?
